Fig. 4.
Knockout of NOXA reduces the sensitivity of tumor cells to CAR T-cell therapy in vivo. a Experimental timeline comparing the susceptibility of sgCONT Nalm6 and NOXAKO Nalm6 tumor-bearing mice to CD19 CAR T cells. b Nalm6 tumor progression as evaluated by bioluminescence imaging (n = 5 mice per group). c Mouse tumor burden (average radiance). The indicated P value was determined by two-way ANOVA test. d Survival of mice inoculated with sgCONT or NOXAKO Nalm6 cells and treated with control T cells or CD19 CAR T cells. Log-rank tests were used to determine statistical significance. Values are shown as the mean ± SD of five mice per group. ns: not significant (P > 0.05); *P < 0.05, **P < 0.01, and ***P < 0.001